{"nctId":"NCT01450761","briefTitle":"Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","startDateStruct":{"date":"2011-12-13","type":"ACTUAL"},"conditions":["Small Cell Lung Carcinoma"],"count":1351,"armGroups":[{"label":"Ipilimumab+Etoposide+Cisplatin/Carboplatin","type":"EXPERIMENTAL","interventionNames":["Biological: Ipilimumab","Drug: Etoposide","Drug: Cisplatin","Drug: Carboplatin"]},{"label":"Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo matching Ipilimumab","Drug: Etoposide","Drug: Cisplatin","Drug: Carboplatin"]}],"interventions":[{"name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"]},{"name":"Placebo matching Ipilimumab","otherNames":[]},{"name":"Etoposide","otherNames":["Etopophos","Neoposid","Eposin"]},{"name":"Cisplatin","otherNames":["Platinol"]},{"name":"Carboplatin","otherNames":["Paraplatin"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.\n\nInclusion Criteria:\n\n* Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)\n* Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n\nExclusion Criteria:\n\n* Prior systemic therapy for lung cancer\n* Symptomatic Central Nervous System (CNS) metastases\n* History of autoimmune disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy","description":"Overall Survival was defined as the time from the date of randomization until the date of death from any cause. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.97","spread":null},{"groupId":"OG001","value":"10.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in All Randomized Participants","description":"Overall Survival was defined as the time from the date of randomization until the date of death from any cause. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.22","spread":null},{"groupId":"OG001","value":"9.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Time in Participants Who Have Received at Least One Dose of Blinded Study Therapy","description":"Progression-Free Survival was defined as the time from the date of randomization to the date of progression per modified World Health Organization (mWHO) criteria or death, whichever occured first. A participant who died without reported progression per mWHO criteria was considered progressed on the date of death. For those participants who remained alive and did not progress, PFS was censored on the date of last evaluable tumor assessment. For those participants who remained alive and had no recorded post-baseline tumor assessment, PFS was censored on the day of randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.63","spread":null},{"groupId":"OG001","value":"4.44","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":316,"n":562},"commonTop":["Neutropenia","Nausea","Alopecia","Anaemia","Fatigue"]}}}